Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Int J Chron Obstruct Pulmon Dis ; 12: 1961-1971, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28740376

RESUMO

PURPOSE: To evaluate fluticasone propionate/formoterol (FP/FORM) in COPD. PATIENTS AND METHODS: COPD patients with forced expiratory volume in 1 s (FEV1) ≤50% predicted and ≥1 moderate/severe COPD exacerbation in the last 12 months were randomized to FP/FORM 500/20 or 250/10 µg bid, or formoterol (FORM) 12 µg bid for 52 weeks. The primary outcome was the annualized rate of moderate/severe COPD exacerbations. RESULTS: In total, 1,765 patients were randomized. There were fewer discontinuations with FP/FORM 500/20 µg (20.6%) and 250/10 µg (24.0%) compared with FORM (26.1%). None of the two FP/FORM doses reduced the moderate/severe exacerbation rate versus FORM (rate ratios [RR]: 0.93; P≤0.402). There was a trend toward a lower moderate/severe exacerbation rate with FP/FORM 500/20 µg versus FORM in patients with ≥2 exacerbations in the preceding year (RR: 0.79; P=0.084). Pre- and post-dose FEV1 and forced vital capacity were greater with FP/FORM 500/20 µg versus FORM (P≤0.039). There was a trend toward a lower EXAcerbations of Chronic pulmonary disease Tool (EXACT) exacerbation rate with FP/FORM 500/20 µg versus FORM (RR: 0.87; P=0.077). There were more St George's Respiratory Questionnaire for COPD (SGRQ-C) responders with FP/FORM 500/20 µg than FORM (odds ratios [OR] at weeks 6, 23 and 52 ≥1.28; P≤0.054). EXACT-respiratory symptoms total and breathlessness scores were lower with both FP/FORM 500/20 µg and 250/10 µg versus FORM (P≤0.066). Acute ß2-agonist-induced effects and 24-hour Holter findings were similar for all treatments. Mean 24-hour urinary cortisol was similarly reduced with both FP/FORM doses. Radiologically confirmed pneumonia was seen in 2.4%, 3.2% and 1.5% of FP/FORM 500/20 µg, FP/FORM 250/10 µg and FORM-treated patients, respectively. Adverse events were otherwise similar across treatment groups. CONCLUSION: FP/FORM did not reduce exacerbation rates versus FORM. Numerical benefits were observed with FP/FORM 500/20 µg versus FORM for secondary variables, including lung function, EXACT exacerbations, SGRQ-C and EXACT-respiratory symptoms total and breathlessness scores. Few efficacy differences were evident between FP/FORM 250/10 µg and FORM. Pneumonia was more frequent in FP/FORM-treated patients, although the absolute difference was low. Adverse events were otherwise similar between treatments.


Assuntos
Agonistas de Receptores Adrenérgicos beta 2/uso terapêutico , Androstadienos/uso terapêutico , Broncodilatadores/uso terapêutico , Etanolaminas/uso terapêutico , Pulmão/efeitos dos fármacos , Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico , Agonistas de Receptores Adrenérgicos beta 2/efeitos adversos , Adulto , Idoso , Androstadienos/efeitos adversos , Broncodilatadores/efeitos adversos , Progressão da Doença , Método Duplo-Cego , Combinação de Medicamentos , Etanolaminas/efeitos adversos , Europa (Continente) , Feminino , Fluticasona , Volume Expiratório Forçado , Fumarato de Formoterol , Humanos , Pulmão/fisiopatologia , Masculino , Pessoa de Meia-Idade , Doença Pulmonar Obstrutiva Crônica/diagnóstico , Doença Pulmonar Obstrutiva Crônica/fisiopatologia , República da Coreia , Índice de Gravidade de Doença , África do Sul , Inquéritos e Questionários , Fatores de Tempo , Resultado do Tratamento , Capacidade Vital
2.
Ann Oncol ; 22(8): 1812-23, 2011 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-21324953

RESUMO

BACKGROUND: The European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study provided sorafenib to advanced renal cell carcinoma (RCC) patients in whom previous systemic therapy had failed. The study assessed the safety and use of sorafenib for the treatment of advanced RCC in a large community-based patient population across 11 countries in Europe. PATIENTS AND METHODS: EU-ARCCS was a single-arm, open-label trial of sorafenib in advanced RCC patients. End points included safety, time to progression, progression-free survival (PFS), and disease control rate (DCR). Subgroup analyses included age, Eastern Cooperative Oncology Group performance status, histology, prior therapy, and number and sites of metastases. RESULTS: About 1159 advanced RCC patients were enrolled. Most patients (94%) experienced drug-related adverse events (AEs) of any grade, with the most common grade ≥3 AEs including hand-foot skin reaction (13%), diarrhea (7%), fatigue (7%), hypertension (6%), and rash/desquamation (5%). The incidence of AEs in the subgroups was similar to that in the overall population. Median PFS was 6.6 months; DCR at ≥8 and ≥12 weeks was 85% and 78%, respectively. CONCLUSIONS: The sorafenib safety profile in European community-based practice settings was similar to that reported in clinical trials. The heterogeneous advanced RCC patient population in EU-ARCCS permitted assessment of sorafenib in important subpopulations of advanced RCC patients.


Assuntos
Antineoplásicos/efeitos adversos , Benzenossulfonatos/efeitos adversos , Carcinoma de Células Renais/tratamento farmacológico , Ensaios de Uso Compassivo , Neoplasias Renais/tratamento farmacológico , Piridinas/efeitos adversos , Adolescente , Adulto , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Antineoplásicos/administração & dosagem , Antineoplásicos/uso terapêutico , Benzenossulfonatos/administração & dosagem , Benzenossulfonatos/uso terapêutico , Intervalo Livre de Doença , Europa (Continente) , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Niacinamida/análogos & derivados , Compostos de Fenilureia , Piridinas/administração & dosagem , Piridinas/uso terapêutico , Sorafenibe , Resultado do Tratamento
3.
Eur J Clin Nutr ; 65(2): 160-6, 2011 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-21139631

RESUMO

BACKGROUND: Pre-prepared commercial foods (convenience foods, CFs) are one aspect of modern dietary habits. The present paper examines the association between CF consumption and dietary quality or body weight status in a sample of German children and adolescents. METHODS: Linear mixed-effect regression analyses using data from 586 participants (296 boys, 3-18 years) in the Dortmund Nutritional Anthropometric Longitudinally Designed Study, who yearly completed 1890 3-day dietary records and anthropometric measurements in 2004-2008, was used. RESULTS: CF intake (percent total food intake) showed no significant association with macronutrient intakes (%E), with exception of a significant positive association with polyunsaturated fatty acid (PUFA) intake (P<0.0001). Considering only high-energy-dense (ED)-CF (40% of the CF intake), there was a significant negative association with total protein, carbohydrate and saturated fatty acid intake (%E) (P<0.05), and a positive with total fat and PUFA (P<0.01). The nutrient quality index (harmonic mean of 10 vitamins and minerals as the percentage of the reference intakes) showed a significant negative trend with increased consumption of CF (P=0.0013). No significant association between baseline or change in consumption of CF and baseline or change in parameters of body weight (standard deviation score of body mass index (weight/height(2)) or percentage body fat (%BF) estimated from skinfolds) was found. Among boys, baseline consumption of high-ED-CF significantly predicted change in %BF during the study period (ß 0.104, P=0.0098). CONCLUSIONS: Our results point to an impairment of dietary quality with high consumption of CF and to a small but positive association between consumption of high-ED-CF in boys and weight.


Assuntos
Peso Corporal/fisiologia , Dieta/normas , Fast Foods , Comportamento Alimentar , Adolescente , Fenômenos Fisiológicos da Nutrição do Adolescente , Antropometria , Criança , Fenômenos Fisiológicos da Nutrição Infantil , Pré-Escolar , Estudos de Coortes , Dieta/estatística & dados numéricos , Registros de Dieta , Inquéritos sobre Dietas , Carboidratos da Dieta/administração & dosagem , Gorduras na Dieta/administração & dosagem , Proteínas Alimentares/administração & dosagem , Ingestão de Energia , Feminino , Humanos , Estudos Longitudinais , Masculino , Valor Nutritivo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...